











Question 1

What are the 2 **priority** antibiotic stewardship interventions recommended by the CDC?

- A. Audit & feedback + preauthorization
- B. Antibiotic timeouts + penicillin allergy assessments
- C. Guidelines + formulary restrictions
- D. Peer comparison + de-escalation









Conceptualizing Varied Actions

One way to conceptualize varied strategies is to place them into 4 categories based on 2 factors

- Do they occur **BEFORE** or **AFTER** prescribing
- Do they require ACTIVE or PASSIVE interaction with prescribers
- · A mix of passive & active approaches, before and after prescribing is likely to have the greatest impact

Passive	Active				
Indirect interactions in which prescribers seek out information on prescribing decisions if they choose to do so	Direct interactions in which AS team or interprescribing, restricting or persuading prescribing				
GuidelinesEducation	 Preauthorization Prospective audit + feedback Clinical decision pathways, order sets Peer comparisons/provider feedback Antibiotic time-outs Automatic stop orders 	 Dose optimization protocols IV to PO conversions ASP rounds/hand-shake rounds Allergy initiatives Cascading or tiered abx susceptibility reports 			
	Automatic stop orders	U			







• Edu	Datient clinic RCTs ation alone - 5-20% reduction ation + Audit/Feedback of prescriber-specific aggregate abx use - 50-75% reduction	
Guidel abx 	passive Interventions effective e + Education of guidelines (inpatient) onsumption declined 26% priate use improved 26%	
• 10%	te + Education (academic detailing, presentations) ncrease in g/l adherence \rightarrow 8% reduction 30-d mortality, improved patient outcomes, er LOS	
Gerber J., et al. JAM. Cisneros J., et al. CIT Dean et al Chest 200	4:20(1):82-88.	





Overcoming Barriers

- · Influence P&T decisions by assigning ASP members as part of P&T voting members
- · Obtain appropriate authority from institutional policy & committees
- · Work to establish positive, personal rapport w/ prescribers
- · Establish a streamlined approval process to minimize prescribers time & effort
- Monitor patient outcomes, abx use rates to identify unintended consequences (and report back outcomes, savings to leadership)

Question 2
Audit and feedback is the process of reviewing antibiotics utilized (for clinical scenario/infections) and providing feedback to prescribers in order to improve antibiotic use.
True / False?
A. True B. False
To protect and improve the health and environment of all Kansans



L

Prospective Audit & Feedback

Choosing What to Audit

- Abx based on potential for misuse:
 - Spectrum (e.g. piperacillin/tazobactam)
 - Toxicities (vancomycin)
 - High consumption (daptomycin, linezolid)
 - IV to PO
 - Coverage (double anaerobic)
 - Clinical scenarios
 - S. auris bacteremia, candidemia
 - Ventilator or community acquired pneumonias

Operationalize

- AS physician or pharmacist performs audit
- Combination review (if pharmacist providing feedback, reviews w/ physician)
- Manual review vs software (provides realtime review of targeted abx, scenarios)
- Provides direct feedback via
 - Rounds
 - Pager
 - Phone
 - EMR
 - Written
- Method of feedback take into consideration personnel availability, institutional culture/norms, size of facility/feedback needed, consider certain days of the week

To protect and improve the health and environment of all Kansa

21

Audit & Feedback Success Examples

Small community hospital, prospective auditing

- Chose multiple, prolonged or high-cost abx
- Initial perceptions of loss of autonomy, work w/ P&T took into considerations (legal liability if
 providers rejected AS's recommendations, so chose not to enter into chart not subject to legal
 discovery), no suggestions made if data insufficient for comfortable decision and went after
 "low-hanging abx fruit" not complicated mgmt issues
- · Pharmacist spent ~8h / wk , reached out three times weekly
- · 69% recommendations accepted & implemented, 26% were rejected and 5% cancelled
- · Cost savings enabled support of pharmacist + ID physician part-time

ASPs using clinical decision support software

- Decreased number of patients requiring review by 84%
- Decreased abx use up to 37%
- · Decreased expenditures by \$400/patient
- Decreased LOS

LaRocco A., et al. CID 2003;37(5):742-43. Glowacki R., et al CID 2003;37(1):59-64 Fraser G., et al. Arch Interm Med 1997;187(15):1689-94 Solomon D., et al Arch Intern Med 2001;161(15):1897-1902.

Pharmaceutical Interventions

Antibiotic "time-outs": Providers review, document abx choice, dose, duration, micro data, indication IV to PO conversions: Auto-conversion for IV to PO formulations w/ high bioavailability

Dose Optimization

Automatic Stop orders: Use of abx permitted for a defined period, then requires approval for continuation

Benefits

- Improves abx selections, dosing
- Improved patient outcomes (dose optimization)
- Awareness to abx/durations
- Improves lab monitoring/follow-up
- Minimal resources required
- Integrated into EMR

Challenges

- Ongoing educational efforts, routine assessments, pharmacy workflow integration (dose optimization, stop orders)
- Inadvertent discontinuation (stop orders)
- "Alert fatigue" or providers may complete documentation but not change abx decisions (time-outs)

23



Pharmaceutical Continuing Education

MAD-ID

- \$500 per physician, pharmacist, nurse
- \$350 per trainee
- discounts for larger groups
- online, teleconference and practical components included

https://mad-id.org/



SIDP - Antibiotic Stewardship Certificate

- \$750 per pharmacist
- \$500 per trainee
- Phase 1 is self-study
- Phase 2 is live webinar
- Phase 3 includes a skills component at the practice site <u>https://sidp.org/Stewardship-Certificate</u>

KS Reimbursement Program :

https://www.khconline.org/14-khc-initiatives/402-haiar#SIDP



25

Peer Comparison

Comparison of provider antibiotic prescribing to their peers

- Behavior change is a major challenge for ASPs, especially when prescribers don't realize their prescribing patterns differ from standard or optimal practice
- Being an "outlier" or "not a top performer" are very motivating

Benefits

- · Improves abx prescribing
- Identifies specific prescribers to target educational efforts & interventions
- Provides positive reinforcement to top performers as well as incentives to change behavior in poor performers

Challenges

- Standardized EMR to collect, analyze data confidential for feedback
- Requires adequate sample of prescribers or practices for valid comparisons
- Request development of accepted definition of "appropriate use"
- Prescriber or institutional push-back













Clinical Decision Pathways

Syndrome based guidance for abx selection, diagnostics at the time of order entry (e.g., order sets, best practice alerts, embedded tools)

Benefits

- Integrate guideline and awareness
- Integrates dose optimization and abx selections
- Standardizes abx selections

Challenges

- · Declining order set use
- IT to design, implement, maintain updates

Antwerp, Dean Male, 46 year old, 05/15/1972		Epic #: 52916085 1777HC #: 2405084 Unit: None, E Fret Lang:	Chel Camptert Chest Pain, Cough an	dí	Uergies	he None	mi None
+++	ED Navigator	1910 Nevigiter 4- Dage 4	COULANIAN COULAND	arge HRaderances #71	Team @Phill45 -	Charling Reminders 11	REferigitor
Insport	Banners *	Hemoptysia		1-Yes 0-No			
Commany Chart Review	Expected Notes Triage Summary	Molighancy with treatme palliative	ont within 6 months or	C 1-Tes D-No			
Results Red	Vitals Report Chief Complaint	Score	Deo				
Problem List	Home Medications	Wells' Criteria Recor	mandation				
telory.	Allengies Hittlory		low. PERC Fulle should be calcul	lated per hospital pectocol.			
Notes	EKG Reven			and be reduced because			_
Demographic.	Provider Notes Report Notes	~ PERC					
Lotters	Procedure Notes		pulated from Wells' Criteria)	(NO			
Leaces	Universal Protocol	HR/Pulse > 90 (autopop	ulated from Wells: Critana)	C No			
Heckations .	Behavior Hallway End	Hemophysis (autopopub	ted from Wells' Oriteria)	2 No			
Marcias	Room Immediately	Age > 49		Age from patient chart	46	C Use the	value Enter another value
Indecs	Sepain	SaO2, on room air < 95	6	Lowest-recorded \$202	0 60	C Uwilli	unite Enter another value
	PE Dx Tool POMP			in encounter			
hter injections	GATESTART	Unilateral log owelling		L' Yes No			
444	ED CareSTART N	Recent surgery or town hospitalization in previo	a (sequiring intubation or	T Yes No			
WR.	CHRISTART	Hormone use	C/ 4 Manuell	C Yes No			
Flowsheets	015515	reported the					
			To protect and i		1.1		C 11 12

33

Microbiologic Initiatives

Diagnostic technologies which provider rapid ID and/or susceptibility info compared to traditional micro methods: for best effect, integrate into active ASP initiatives (e.g., audit & feedback)

Cascading or tiered abx susceptibilities on micro reports

Antibiogram /guidelines

Benefits

- Improves time to diagnosis
- Improved patient outcomes (e.g., rapid blood cx ID)
- Improved abx selections
- More rapid de-escalation (e.g., procalcitonin/viral URIs)

Challenges

- Provider frustration (e.g., cascading)
- Inaccurate assumptions of susceptibilities for agents not reported

lide certain antibio usceptible but les	Bummary ® Staphylococcus ® mecA	1.00 Detected 1.00 Detected	* 8. aureus 1.00 Detected	Provider Actionable AST data conveyed as the organism name	
ERATE SERATIA MACESCENS REATE SERATIA MACESCENS RATIA MACESCENS RATIA MACESCENS RATIA MACESCENS RATIA MACESCENS RATIA MACESCENS REATE SERATIA MACESCENS RATIA MACESCENS		Detail * Baphylococeu S. epidermidis * mocA B. pagalotae E. pagalotae E. faceulis vanA Lataria	1.00 Detected Not Detected 1.00 Detected Not Detected		B. Burreue 1.00 Detected S. lugdurensile Nic Detected Breptococcus Nic Detected B. programma Nic Detected B. engineers gp. Nic Detected E. tenclum Nic Detected van® NiA
OULD BE CONSIDERED. Susceptibility	D BE CONSIDERED.				
Susceptionity	Serratia marcescens MIC	EHR			\sum
Ampicillin	>16 RESISTANT Resistant	Specimen Type	BLOOD, VENOUS		$\langle \rangle$
Ampicillin/sulbactam	>16/8 RESIS Resistant	Special Handling	NONE		×
Cefazolin	>16 Resistant ¹	Gram Stain Result		COCCI RESEMBLING STAPHYLOCO	
Cefepime	<=2 SUSCEPT Sensitive		METHICILLIN RE METHODS. NEGAT	SISTANT STAPHYLOCOCCUS AURE	US DETECTED BY MOLECULAR
Ceftazidime	<=1 SUSCEPT Sensitive			TESTED. SEE TEST DIRECTORY	FOR ASSAY INFORMATION.
Ceftriaxone	<=1 SUSCEPT Sensitive	Organism 1	METHICILLIN RE	SISTANT STAPHYLOCOCCUS AURED	IS
Cefuroxime	>16 RESISTANT Resistant				
Ciprofloxacin	<=1 SUSCEPT Sensitive				
Ertapenem	<=0.5 SUSCE Sensitive		イケ		
Gentamicin	<=1 SUSCEPT Sensitive		\checkmark		
Levofloxacin	<=0.25 SUSC Sensitive				CA: None
Piperacill/Tazob TMP SULFA	<=4 SUSCEPT Sensitive <=2/38 SUSC Sensitive		IPC		nguage: English ection: MRSA
TMP SULFA	<=2/38 SUSC Sensitive				plation: Contact
		_	_		

Diagnostic Stewardship

Technologic advancements, many tests but need to determine how best to use them

Advantages	Disadvantages				
Increased diagnostic yields (1 sample, multiple targets)	False positive (cross-reactivity or nonspecific amplification caused by mult. primers/target present in reaction)				
Conserve & optimize analysis of samples difficult to obtain (e.g., synovial, csf)	Overly sensitive - positive results of unclear significance				
Simplifies ordering algorithm as only 1 test needs requested	High cost of commercial kits & instruments				
Potential saving in reagents by testing mult. organisms at once compared to testing each separately	Added costs of testing targets may not be necessary				
Standardizes testing					



Question 5What ways are you currently implementing to improve antibiotics in your facility
(all that apply)?A. Treatment guidelinesI. Clinical Decision support toolsB. Formulary restrictionsJ. VaccinationsC. Dose optimization/IV to PO conversionsK. Microbiology reporting/cascadingD. Time sensitive abx stop ordersK. Microbiology reporting/cascadingE. Audit & feedbackF. Peer comparisonG. EducationH. Penicillin assessments



Resources

Guidelines

CAP (2019)

https://www.atsjournals.org/doi/full/10.1164/rccm.2 01908-1581ST

C. diff (2021) https://doi.org/10.1093/cid/ciab549

HAP/VAP (2016) https://doi.org/10.1093/cid/ciw353

SSTI (2014) https://doi.org/10.1093/cid/ciu296

Surgical prophylaxis

IDSA: <u>https://doi.org/10.2146/ajhp120568</u> ASHP: https://www.ashp.org/surgical-guidelines

UTI & ASB (2019)

https://doi.org/10.1093/cid/ciq257

Tools

Needs Assessment / Current State

https://www.kdhe.ks.gov/DocumentCenter/View/14462/Table-14---Current-State-Assessment-DOCX

Most common facility antibiotics assessemnt https://www.kdhe.ks.gov/DocumentCenter/View/14459/Table-11---Summary-of-Facility-Antibiotics-DOCX

Protocols

IV to PO protocol

https://www.kdhe.ks.gov/DocumentCenter/View/14466/Template-4---ASP-IV-to-PO-Protocol-DOCX

PCN allergy

https://www.kdhe.ks.gov/DocumentCenter/View/14467/Template-5---ASP-PCN-Allergy-Protocol-DOCX







